Antibiotic therapy for treatment in relapse of intestinal Crohn's disease: A prospective randomized study
The DOI matches its Crossref record.
Abstract
We have undertaken a prospective randomized trial of one month's antimicrobial therapy for patients with symptomatic relapse of Crohn's disease. Criteria for entry included two major symptoms: fever, abdominal pain, diarrhea, weight loss, abdominal mass or complications (excluding perianal disease); and two hematologic abnormalities: hemoglobin, ESR, albumin, C reactive protein, iron, or total iron binding capacity. Patients were monitored for the aforementioned clinical and hematologic (hemoglobin, albumin, CRP) parameters over six weeks and for changes in fecal flora. Randomization was to four groups: metronidazole alone (M), cotrimoxazole alone (C), metronidazole and cotrimoxazole (C plus M), or double placebo (P). Seventy-two patients entered the study (18 = M, 16 = C, 21 = C plus M, 17 = P). After two weeks, improvement was reported as follows: M = 67 percent, C = 17 percent, C plus M = 71 percent, P = 35 percent. In the metronidazole group, two patients required surgery and one had troublesome side effects. In the cotrimoxazole group, two had side effects. In the combined group (C plus M), four had troublesome side effects and two of the placebo group (P) required operation. By four weeks, there was no difference in response among the groups: (M = 44 percent, C = 62 percent, C plus M = 57 percent, P = 41 percent). Antimicrobials had no effect on fecal flora or hematologic parameters. These results indicate that antimicrobials have little therapeutic potential for relapse of intestinal Crohn's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Rutgeerts, P., Hiele, M., Geboes, K., Peeters, M., Penninckx, F., Aerts, R., & Kerremans, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90121-3 · Cited by 743
The Gastrointestinal Microbiome: A Review
Barko, P. C., McMichael, M. A., Swanson, K. S., & Williams, D. A. (2018) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.14875 · Cited by 750
Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis
Khan, K. J., Ullman, T. A., Ford, A. C., Abreu, M. T., Abadir, A., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.72 · Cited by 569
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
Sutherland, L., Singleton, J., Sessions, J., Hanauer, S., Krawitt, E., Rankin, G., Summers, R., Mekhjian, H., Greenberger, N., & Kelly, M. (1991) · Gut · doi:10.1136/gut.32.9.1071 · Cited by 528
Metronidazole: A Therapeutic Review and Update
Freeman, C. D., Klutman, N. E., & Lamp, K. C. (1997) · Drugs · doi:10.2165/00003495-199754050-00003 · Cited by 473
Wlodarska, M., Willing, B., Keeney, K. M., Menendez, A., Bergstrom, K. S., Gill, N., Russell, S. L., Vallance, B. A., & Finlay, B. B. (2011) · Infection and Immunity · doi:10.1128/iai.01104-10 · Cited by 382
Current and emerging drugs for the treatment of inflammatory bowel disease
Triantafillidis, J. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s11290 · Cited by 289
Aktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014
Preiß, J., Bokemeyer, B., Buhr, H., Dignaß, A., Häuser, W., Hartmann, F., Herrlinger, K., Kaltz, B., Kienle, P., Kruis, W., et al. (2014) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0034-1385199 · Cited by 188
Prantera, C., Lochs, H., Grimaldi, M., Danese, S., Scribano, M. L., & Gionchetti, P. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.032 · Cited by 176
Metadata
- Authors
- Ambrose, N. S., Allan, R. N., Keighley, M. R. B., Burdon, D. W., Youngs, D., Barnes, P., & Lennard-Jones, J. E.
- Venue
- Diseases of the Colon & Rectum
- Published
- 1985-02
- Volume
- 28
- Issue
- 2
- Pages
- 81-85
- ISSN
- 0012-3706 (ISSN-L)
- OpenAlex
- W2790369599
- Cited by
- 107
- References
- 0
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.